• Aligos Therapeutics will present positive hepatitis research findings at The Liver Meeting in Denver, November 5-9, 2026.
• Pevifoscorvir sodium reduced inflammatory markers in a clinical follow-up study; levels rose during subsequent entecavir-only treatment.
• Preclinical findings suggest pevifoscorvir sodium could better prevent hepatitis B viral DNA integration than nucleos(t)ide analogs.
• ALG-170675 outperformed bepirovirsen in reducing hepatitis B surface antigen in mice; the candidate is in Phase 1 testing in China with Amoytop.
• Experimental antisense treatment ALG-215007 strongly inhibited hepatitis delta virus replication in laboratory studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9871577) on November 05, 2026, and is solely responsible for the information contained therein.